JP2016532456A - 改変型抗炎症性タンパク質及び使用方法 - Google Patents

改変型抗炎症性タンパク質及び使用方法 Download PDF

Info

Publication number
JP2016532456A
JP2016532456A JP2016543270A JP2016543270A JP2016532456A JP 2016532456 A JP2016532456 A JP 2016532456A JP 2016543270 A JP2016543270 A JP 2016543270A JP 2016543270 A JP2016543270 A JP 2016543270A JP 2016532456 A JP2016532456 A JP 2016532456A
Authority
JP
Japan
Prior art keywords
tmp
disease
protein
modified
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016543270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532456A5 (enExample
Inventor
ルーカス、アレックス
ピカリング、ダレン
リーチ、アンドリュー
Original Assignee
ジェームス・クック・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903588A external-priority patent/AU2013903588A0/en
Application filed by ジェームス・クック・ユニバーシティー filed Critical ジェームス・クック・ユニバーシティー
Publication of JP2016532456A publication Critical patent/JP2016532456A/ja
Publication of JP2016532456A5 publication Critical patent/JP2016532456A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016543270A 2013-09-18 2014-09-18 改変型抗炎症性タンパク質及び使用方法 Pending JP2016532456A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013903588A AU2013903588A0 (en) 2013-09-18 Modified anti-inflammatory proteins and method of use
AU2013903588 2013-09-18
PCT/AU2014/050240 WO2015039189A1 (en) 2013-09-18 2014-09-18 Modified anti-inflammatory proteins and method of use

Publications (2)

Publication Number Publication Date
JP2016532456A true JP2016532456A (ja) 2016-10-20
JP2016532456A5 JP2016532456A5 (enExample) 2017-08-31

Family

ID=52688012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016543270A Pending JP2016532456A (ja) 2013-09-18 2014-09-18 改変型抗炎症性タンパク質及び使用方法

Country Status (8)

Country Link
US (3) US10822395B2 (enExample)
EP (2) EP4509188A3 (enExample)
JP (1) JP2016532456A (enExample)
CN (1) CN105745223A (enExample)
AU (1) AU2014324094B2 (enExample)
CA (1) CA2924220A1 (enExample)
WO (1) WO2015039189A1 (enExample)
ZA (1) ZA201602304B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105745223A (zh) * 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
WO2022192955A1 (en) * 2021-03-17 2022-09-22 James Cook University Proteins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134822A1 (en) * 2012-03-13 2013-09-19 James Cook University Method for treating inflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US6090790A (en) 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
DE69233035D1 (de) 1991-12-24 2003-06-05 Harvard College Gezielte punkt-mutagenese von dna
US6756211B1 (en) 1992-05-11 2004-06-29 Corvas International, Inc. Neutropohil inhibitors
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
WO1999047070A1 (en) 1998-03-18 1999-09-23 Wake Forest University Improved implantable biomaterials, compositions and methods for their preparation and uses thereof
JP2000007575A (ja) 1998-06-17 2000-01-11 Fuji Chem Ind Ltd 抗アレルギー剤
AU2001252278A1 (en) 2000-04-05 2001-10-15 Ipf Pharmaceuticals Gmbh Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance
JP4426179B2 (ja) 2000-12-18 2010-03-03 アライバ ファーマシューティカルズ，インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
DE10138550A1 (de) 2001-08-06 2003-02-20 Wolfgang E Berdel Verwendung von TIMP-1 als Immunsuppressivum
US7303752B2 (en) 2001-10-17 2007-12-04 The George Washington University Hookworm vaccine
NZ536796A (en) 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
US7928132B2 (en) 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
WO2007005672A2 (en) 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
EP1910417A2 (en) 2005-07-29 2008-04-16 Imperial Innovations Limited Compounds
WO2010048432A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US20140274874A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
CN105745223A (zh) 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
AU2014324093A1 (en) * 2013-09-18 2016-04-28 James Cook University Anti-inflammatory proteins and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134822A1 (en) * 2012-03-13 2013-09-19 James Cook University Method for treating inflammation
JP6144288B2 (ja) * 2012-03-13 2017-06-07 ジェームス・クック・ユニバーシティー 炎症を治療する方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
INFECT. IMMUN., vol. 81, no. 6, JPN6018020783, June 2013 (2013-06-01), pages 2104 - 2111, ISSN: 0003812924 *
INFLAMM. BOWEL DIS., vol. 15, no. 4, JPN6018020781, 2009, pages 491 - 500, ISSN: 0003812923 *
MOL. BIOCHEM. PARASITOL., vol. 162, JPN6018020779, 2008, pages 142 - 148, ISSN: 0004024539 *
PARASITES AND VECTORS, vol. 6:156, JPN6018020785, 30 May 2013 (2013-05-30), pages 1 - 11, ISSN: 0003812925 *

Also Published As

Publication number Publication date
CN105745223A (zh) 2016-07-06
CA2924220A1 (en) 2015-03-26
US20160229905A1 (en) 2016-08-11
ZA201602304B (en) 2019-06-26
US12466873B2 (en) 2025-11-11
US11976108B2 (en) 2024-05-07
WO2015039189A1 (en) 2015-03-26
US10822395B2 (en) 2020-11-03
US20240400649A1 (en) 2024-12-05
US20210061886A1 (en) 2021-03-04
EP4509188A3 (en) 2025-04-02
AU2014324094A1 (en) 2016-05-05
AU2014324094B2 (en) 2019-03-14
EP3046937A4 (en) 2017-04-26
EP3046937A1 (en) 2016-07-27
EP4509188A2 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
JP2021063117A (ja) 抗炎症性ポリペプチド
CN102959082B (zh) 用于治疗自身免疫性和变应性疾病的新组合物和方法
US12466873B2 (en) Modified anti-inflammatory proteins and method of use
JP2002518458A (ja) アジュバント療法
WO2013160865A1 (en) Immunotolerizing fusion proteins for treatment of multiple sclerosis
CN113144178A (zh) 采用精氨酸酶i调节免疫系统的方法和组合物
JP2018508522A (ja) 抗炎症性ポリペプチド
CN110381990A (zh) 马的瘙痒症的治疗
CN101318017A (zh) 一种预防和/或治疗过敏性哮喘的疫苗
JP2024517476A (ja) 自己免疫を治療するためのｈｌａ対立遺伝子のポケット操作
WO2022127825A1 (zh) 针对新型冠状病毒感染的疫苗组合物
US9637527B2 (en) Method for treating inflammation with an Ac-TMP-2 protein
CN102215873A (zh) 树突状细胞调节分子
JP2017131234A (ja) 免疫変調剤およびそれらの使用
KR102725058B1 (ko) 엑소좀을 이용하는 covid-19 백신 또는 치료용 약제학적 조성물
WO2018101425A1 (ja) 抗ｔｌｒ９抗体、医薬組成物及びキット
WO2015077442A2 (en) Grass pollen immunogens and methods and uses for immune response modulation
US9676832B2 (en) Dendritic cell inhibitory proteins from ticks
KR20160069204A (ko) 인간 카텔리시딘 ll-37을 포함하는 면역 활성 유도제, 이를 포함한 경구 백신, 및 이를 이용한 면역 활성 유도 방법
WO2015153678A2 (en) Epsigam fusion protein
HK1234336A (en) THE ROLE OF IL-1F7α

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20160428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170721

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190507